Evidence map›Paper›PMID 38686344›Full record

ArticleBio-protocol2024

Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes.

Shreyas G Iyer, Andrea L Kasinski

Abstract read
In one paragraph

Article in Bio-protocol, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shreyas G IyerDepartment of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Andrea L KasinskiDepartment of Biological Sciences, Purdue University, West Lafayette, IN, USA.

Funding

Ligand-mediated, vehicle-free delivery of small RNAsR01CA226259 · NCI · PURDUE UNIVERSITY · PI Andrea L Kasinski · 2018 to 2026
$3.4M
Enhancing miRNA Therapeutics through Vehicle Free DeliveryR01CA205420 · NCI · PURDUE UNIVERSITY · PI Andrea L Kasinski · 2017 to 2026
$2.9M
NCI NIH HHS R01 CA205420NCI NIH HHS R01 CA226259
6 · The paper itself

Abstract

The field of oligonucleotide therapeutics is rapidly advancing, particularly for combating orphan diseases and cancer. However, the intrinsic instability of oligonucleotides, especially RNA, poses a substantial challenge in the face of the harsh conditions encountered intracellularly and in circulation. Therefore, evaluating the stability of oligos in serum is of great significance when developing oligonucleotide therapeutics. This protocol outlines a dependable and reproducible method for preparing oligonucleotide duplexes, coupled with confirmation by gel electrophoresis. Subsequently, the protocol defines a mechanism to assess the stability of the oligo duplexes in serum. This protocol seeks to establish a standardized reference for researchers, enabling them to compare the impact of various modifications on oligo stability and assess the degradation kinetics effectively. Key features • Adaptable for use with small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), and other unmodified and modified oligonucleotides. • Does not necessitate any Biological Safety Level clearance and offers a rapid, cost-effective, and entirely in vitro procedure. • Allows researchers to evaluate multiple modification patterns that, when coupled with targeting activity, allow for selecting the best modification pattern prior to in vivo analysis.

Indexed as

AnnealingDegradation kineticsDuplexGlycerol tolerant gelmicroRNAModified oligonucleotidesOligonucleotide therapeuticsRNARNA InterferenceSerumsiRNAStability

Identifiers

PMID38686344
PMCPMC11056005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.